Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11317877 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL14397178 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL6062459 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL14992459 | 0.82 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3898493 | 0.82 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13709084 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL77639 | 0.80 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2896415 | 0.80 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL31460273 | 0.80 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3970912 | 0.80 | MEN1 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022234867-A1 | SULFONAMIDE HAVING MMP 7-INHIBITING ACTION | 大正製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022133064-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2208726-B1 | Cyclic amide derivatives, and their production and use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2014-08-20 | — | — | EP | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8697865-B2 | Cyclic amide derivative, and its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2698370-A2 | 3-substituted-4-oxo-3,4-dihydro-imidazo-[5,1-d][1,2,3,5]-tetrazine-8-carboxylic acid amides as anticancer agents | Pharminox Limited (GB) | 2014-02-19 | — | — | EP | disclosed |
| US-20130338104-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d]1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | PHARMINOX LIMITED (GB) | 2013-12-19 | — | — | US | disclosed |
| US-6506777-B1 | Method for modulation of CCR-3 or CCR-5 chemokine receptor activity in a mammal in need thereof to treat asthma, allergic rhinitis, dermatitis, conjunctivitis, atherosclerosis or rheumatoid arthritis, which comprises the administration of an | MERCK & CO., INC. | 2003-01-14 | — | — | US | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
| US-6500844-B1 | PIPERIDINYL-1-METHYLCYCLOPENTANES AND STEREOISOMERS, USED AS ANTIINFLAMMATORY AND PROPHYLACTIC AGENTS AGAINST ALLERGIC RHINITIS, DERMATITIS, VISION DEFECTS, ASTHMA, ATHRITIS AND FOR PREVENTION OR DELAY OF AQUIRED IMMUNE DIFICIENCY SYNDROME | MERCK & CO., INC. | 2002-12-31 | — | — | US | disclosed |
| US-6472410-B1 | N-cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000076512-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6136827-A | PIPERIDINE COMPOUNDS AS DRUGS | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | disclosed |
| EP-1003514-A1 | CYCLIC AMINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999004794-A1 | CYCLIC AMINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | SMN1; SMN2 837/4885NPC1 533/4885RAB9A 1520/4885 |
| US-20130338104-A1 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d]1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use | MKI67, CCNI, CDK4 | SMN1; SMN2 1992/4885NPC1 814/4885RAB9A 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.